Phase I/II trial of neoadjuvant intravenous gemcitabine plus intra-arterial cisplatin in muscle-invasive bladder cancer.
Not Applicable
- Conditions
- bladder cancer
- Registration Number
- JPRN-UMIN000013636
- Lead Sponsor
- ippon Medical School Musashokosugi Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
Not provided
Exclusion Criteria
1. women who are pregnant, possibly pregnant or lactating 2.pleural effusion, peritoneal effusion or pericardial effusion which need emergency treatment 3.presence of active infection 4.presence of active double cancer 5.history of drug hypersensitivity reaction 6.presence of severe complication 7.presence of bilateral hydronephrosis (other than the case which was treated by ureteral stent or nephrostomy ) 8.patients inapprppriate for the study entry determined by a doctor
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method pathological complete response rate
- Secondary Outcome Measures
Name Time Method clinical response rate progression free survival overall survival bladder preservation rate adverse drug reaction